CoChat

The effects of nonspecific HIF 1 α inhibitors on development of castrate resistance and metastases in prostate cancer

Open access
Ranasinghe, Weranja K. B., Sengupta, Shomik, Williams, Scott, Chang, Mike, Shulkes, Arthur, Bolton, Damien M., Baldwin, Graham, Patel, Oneel · 2014 · Cancer Medicine
Cited by 36

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Expression of hypoxia‐inducible factor (HIF)1 α increases the risk of castrate‐resistant prostate cancer (CRPC) and metastases in patients on androgen deprivation therapy (ADT) for prostate cancer (PC). We aimed to investigate the effects of nonspecific HIF 1 α inhibitors (Digoxin, metformin, and angiotensin‐2 receptor blockers) on development of CRPC and metastases while on ADT. A retrospective review of prospectively collected medical records was conducted of all men who had continuous ADT as first‐line therapy for CRPC at the Austin Hospital from 1983 to 2011. Association between HIF 1 α inhibitor medications and time to develop CRPC was investigated using actuarial statistics. Ninety‐eight patients meeting the criteria were identified. Eighteen patients (21.4%) were treated with the nonspecific HIF 1 α inhibitors. Both groups had similar characteristics, apart from patients on HIF 1 α inhibitors being older (70 years vs. 63.9 years). The median CRPC‐free survival was longer in men using HIF 1 α inhibitors compared to those not on inhibitors (6.7 years vs. 2.7 years, P = 0.01) and there was a 71% reduction in the risk of developing CRPC (HR 0.29 [95% CI 0.10–0.78] P = 0.02) after adjustment for Gleason score, age, and prostate‐specific antigen (PSA). The median metastasis‐free survival in men on HIF 1 α inhibitors was also significantly longer compared to those on no inhibitors (5.1 years vs. 2.6 years, P = 0.01) with an 81% reduction in the risk of developing metastases (HR 0.19 [CI 0.05–0.76] P = 0.02) after adjustment for Gleason score, age, and PSA. Nonspecific HIF 1 α inhibitors appear to increase the progression‐free survival and reduce the risk of developing CRPC and metastases in patients on continuous ADT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.189

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Ranasinghe, W. K. B., Sengupta, S., Williams, S., Chang, M., Shulkes, A., Bolton, D. M., Baldwin, G., & Patel, O.
Venue
Cancer Medicine
Publisher
Wiley
Published
2014-01-27
Volume
3
Issue
2
Pages
245-251
ISSN
2045-7634 (ISSN-L)
OpenAlex
W2153784080
Cited by
36
References
4
FWCI
4.60
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.